Form 4: IN8BIO CFO McCall Amends Warrant Terms, Exercises Options
SEC Form 4 Filing
IN8BIO's Chief Financial Officer, Patrick McCall, amended and exercised warrants, affecting his holdings of common stock and derivative securities.
Summary
- Patrick McCall, CFO of IN8BIO, INC., filed a Form 4 detailing changes in his beneficial ownership of company securities.
- On April 27, 2025, McCall amended the terms of Series A and Series B warrants.
- The exercise price of 15,000 Series A warrant shares was reduced from $0.45 to $0.1844 per share, and the expiration date was amended to May 2, 2025.
- The exercise price of 20,492 Series B warrants was reduced from $1.50 to $0.45 per share.
- On April 30, 2025, McCall exercised 15,000 Series A warrants at a price of $0.1844, resulting in the acquisition of 15,000 shares of common stock.
- Following these transactions, McCall directly owns 67,071 shares of common stock.
- McCall also holds 5,492 Series A warrants and 20,492 Series B warrants.
Sentiment
Score: 6
Explanation: The sentiment is neutral. While the CFO exercising warrants is generally positive, the amendment of warrant terms could also be seen as a way to ensure the warrants are exercised, potentially diluting shareholder value.
Positives
- The CFO's exercise of warrants could be seen as a positive signal, indicating confidence in the company's future prospects.
Risks
- Warrant amendments and exercises can dilute existing shareholders' equity.
Industry Context
Warrant exercises and amendments are common in the biotechnology industry, often used to incentivize management and secure funding.
Comparison to Industry Standards
- Warrant terms and exercise prices are generally comparable to those offered by similar stage biotech companies.
- Companies like Celldex Therapeutics and Ziopharm Oncology have used similar warrant structures to raise capital and incentivize executives.
Stakeholder Impact
- Shareholders may experience dilution due to the exercise of warrants.
- Employees may view the CFO's actions as a sign of confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2023-12-13 | Original grant date of warrants. |
| 2024-10-04 | Previous amendment of Series A warrants with an exercise price of $0.45 and expiration date of October 4, 2025. |
| 2025-04-27 | Amendment of warrant terms, including reducing the exercise price of 15,000 Series A warrant shares to $0.1844 and the warrant expiration date to May 2, 2025. |
| 2025-04-30 | Exercise of 15,000 Series A warrants at $0.1844 per share. |
| 2025-05-02 | Amended expiration date for 15,000 Series A warrants. |
| 2025-05-07 | Date of Form 4 filing. |
| 2025-10-04 | Expiration date of remaining 5,492 Series A warrants. |
| 2028-12-13 | Expiration date of Series B warrants. |
Keywords
Form 4, IN8BIO, warrants, Patrick McCall, CFO, beneficial ownership, derivative securities, common stock, exercise price, expiration date
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.